(Q44625103)

4 December 2017

title

Phase II study of docetaxel plus enoxaparin in chemotherapy-naive patients with metastatic non-small cell lung cancer: preliminary results (English)

1 reference

4 December 2017

1 reference

1 reference

3

1 reference

4 December 2017

Francisco Robert

1

1 reference

4 December 2017

Elizabeth Busby

series ordinal

2

1 reference

4 December 2017

Robert E Reynolds

series ordinal

4

1 reference

4 December 2017

Delicia E Carey

series ordinal

5

1 reference

4 December 2017

publication date

1 November 2003

1 reference

4 December 2017

1 reference

4 December 2017

volume

42

1 reference

4 December 2017

issue

2

1 reference

4 December 2017

page(s)

237-245

1 reference

4 December 2017

cites work

Coagulation and cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900354-4

7 January 2021

Improved cancer mortality with low-molecular-weight heparin treatment: a review of the evidence

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900354-4

7 January 2021

Antithrombotic therapy in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900354-4

7 January 2021

Low-molecular-weight heparin and cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900354-4

7 January 2021

Fibrin-enhanced endothelial cell organization

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900354-4

7 January 2021

Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900354-4

7 January 2021

Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900354-4

7 January 2021

Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900354-4

7 January 2021

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900354-4

7 January 2021

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900354-4

7 January 2021

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900354-4

7 January 2021

Inhibition of metastases by anticoagulants

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900354-4

7 January 2021

Evaluation of β thromboglobulin levels in cancer patients : Effects of antitumor chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900354-4

7 January 2021

Platelets and malignancy Rationale and experimental design for the VA Cooperative Study of RA-233 in the treatment of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900354-4

7 January 2021

Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900354-4

7 January 2021

Evaluating prethrombotic state in lung cancer using molecular markers

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900354-4

7 January 2021

Plasma D-dimer measurement as a marker of gynecologic tumors: comparison with Ca 125

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900354-4

7 January 2021

D-dimer: a useful marker of disease stage in surgery for colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900354-4

7 January 2021

Plasma levels of D-dimer: a crosslinked fibrin-degradation product in female breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900354-4

7 January 2021

Plasma D-dimer levels in operable breast cancer patients correlate with clinical stage and axillary lymph node status

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900354-4

7 January 2021

Plasma D-dimer level in patients with colorectal cancer: its role as a tumor marker

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900354-4

7 January 2021

The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900354-4

7 January 2021

Heparin abolishes the chemotherapy-induced increase in plasma fibrinopeptide A levels

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900354-4

7 January 2021

Vascular toxicity associated with antineoplastic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900354-4

7 January 2021

Angiogenesis and non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900354-4

7 January 2021

Positive and negative regulation of proliferation and differentiation in tracheobronchial epithelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900354-4

7 January 2021

Role of transforming growth factor-beta 1 in invasion and metastasis in gastric carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900354-4

7 January 2021

Elevated plasma transforming growth factor-beta 1 levels in breast cancer patients decrease after surgical removal of the tumor

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900354-4

7 January 2021

Plasma transforming growth factor-beta 1 in patients with hepatocellular carcinoma. Comparison with chronic liver diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900354-4

7 January 2021

High levels of transforming growth factor beta 1 in patients with colorectal cancer: association with disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900354-4

7 January 2021

Tumor suppressor activity of the TGF-beta pathway in human cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900354-4

7 January 2021

TGF-beta signaling in tumor suppression and cancer progression

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900354-4

7 January 2021

Transforming growth factor-beta1 level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900354-4

7 January 2021

Actions of heparin that may affect the malignant process

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900354-4

7 January 2021

Subcutaneous heparin treatment increases survival in small cell lung cancer. "Petites Cellules" Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900354-4

7 January 2021

Peri-operative heparin: a possible adjuvant to surgery in colo-rectal cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900354-4

7 January 2021

10.1016/S0169-5002(03)00354-4

Identifiers

DOI

1 reference

4 December 2017

1 reference